Revisiones en Cáncer H0152
Resumen| PDF

Revisión

Emesis y quimioterapia. Papel de los setrones


Publicado: 2023-03-29

Logo Descargas   Número de descargas: 17388      Logo Visitas   Número de visitas: 927      Citas   Citas: 0

Compártelo:


La emesis por quimioterapia ha sido considerada clásicamente como un efecto adverso frecuente y con importantes implicaciones en la adherencia a los tratamientos oncológicos y la calidad de vida de los pacientes oncológicos. El desarrollo de fármacos antagonistas del receptor 5-HT3 ha supuesto una revolución en el tratamiento de este problema, siendo uno de los principales avances de la oncología moderna, y ha hecho posible que en la actualidad contemos con protocolos bien definidos basados en diferentes formulaciones y vías de administración con objetivo de ofrecer un mejor control sintomático a nuestros pacientes. En este artículo procederemos a hacer una revisión de estos fármacos y su uso en la emesis por quimioterapia.

Palabras Clave: Emesis por quimioterapia. Setrones.



Gines Rubio J, Sánchez Pedroche A. Antieméticos y quimioterapia: evolución histórica y estudio comparativo de los antagonistas de la serotonina. Recomendaciones actuales. Farm Hosp 2000;24:187-214.
Morran C, et al. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.
Br Med J 1979;1:1323-4.
Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 1989;64(5):1117-22.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100(10):2261-8.
American Society of Clinical Oncology. ASCO 50th anniversary poll names the top 5 advances from the past 50 years. September 17, 2014.
Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008
Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987.
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-21.
De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;113(11):834-40.
Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995;13(5):1242-8.
Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996;14(8):2242-9.
Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016;374(14):1356-67.
Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14(10):1570-7.
Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 2008;9:501-4.
Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006;19:606-11.
Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-31.
Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JW, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 2011;33(1):33-43.
Ward MB, Kotasek D, McKinnon RA. Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist antiemetic efficacy. Pharmacogenomics 2008;9:1027-33.
Fasching PA, Kollmannsberger B, Strissel PL, Niesler B, Engel J, Kreis H, et al. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol 2008;134:1079-86.
Candiotti KA. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? J Symp Pharmacogenomics 2005;102(3):543-9.
Hsu YC, Chen CY, Tam KW, Hsu CY. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021;77(11):1597-609.
Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15(9):1023-33.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10(2):115-24.
Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17(9):1441-9.
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al.; 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy- induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98(11):2473-82.
Popovic M, Warr DG, Deangelis C, Tsao M, Chan KK, Poon M, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2014;22(6):1685-97.
Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L, et al. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 2018;26(8):2519-49.
Hsu YC, Chen CY, Tam KW, Hsu CY. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021;77(11):1597-609.
Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014;25(7):1340-6.
Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy- induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer 2017;25(4):1127-35.
Zhang L, Lu S, Feng J, Dechaphunkul A, Chang J, Wang D, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2018;29(2):452-8.
Gilmore J, D’Amato S, Griffith N, Schwartzberg L. Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists. Cancer Manag Res 2018;10:1827-57.
Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19(10):1609-17.
Raftopoulos H, Cooper W, O’Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapyinduced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 2015;23(3):723-32.
Raftopoulos H, Boccia R, Cooper W, O’Boyle E, Gralla RJ. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. Future Oncol 2015;11(18):2541-51.
Schnadig ID, Agajanian R, Dakhil C, Gabrail NY, Smith RE Jr, Taylor C, et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol 2016;12(12):1469-81.
Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 2004;9(6):673-86.
De Leon A. Palonosetron (Aloxi): a second-generation 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting. Proc (Bay Univ Med Cent) 2006;19(4):413-6.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark- Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35(28):3240-61.
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al.; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27(suppl 5):v119-v133.

Revisión: Emesis y quimioterapia. Más allá de los setrones y los antagonistas del receptor NK1

Publicado: 2023-03-29 / http://dx.doi.org/

Artículos más populares

Revisión: Valoración de la calidad de vida en pacientes supervivientes de cáncer de cabeza y cuello

El tratamiento del cáncer de cabeza y cuello (CCC)...

Publicado: 2024-03-11

Revisión: Estadios iniciales del cáncer de cabeza y cuello. Papel de la cirugía

En el cáncer de cabeza y cuello la cirugía queda r...

Publicado: 2024-03-12

Revisión: Carcinoma de cabeza y cuello en pacientes no candidatos a platino

El cisplatino es un componente esencial del tratam...

Publicado: 2024-03-19

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.